Discounted Cash Flow Rating

Strong Buy

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Sell

Price to Earnings Rating

Buy

Analyst Rating

Neutral

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Buy

Standard Deviation

Strong Sell

Williams %R

Strong Buy

Average Directional Index

Sell

Insider Trading

Neutral

Wall Street Data Solutions Rating

Neutral

B

Artelo Biosciences, Inc. Common Stock (ARTL)

Pharmaceutical Preparations

https://www.artelobio.com

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors and neurotransmitters that form a biochemical communication network in body. It is focused on discovering, licensing, developing and commercializing treatments that control endocannabinoid system. The company pursues technologies and programs that offer proprietary approaches to cannabinoid-based therapies, also those derived from the cannabis plant and synthetic cannabinoids, as well as new chemical entities and compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare and orphan disease.

505 LOMAS SANTA FE, SUITE 160
SOLANA BEACH, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

10/13/2015

Market Cap

4,099,179

Shares Outstanding

3,190,000

Weighted SO

3,188,959

Total Employees

N/A

Upcoming Earnings

08/08/2024

Similar Tickers

ALRN --.--%

HSTO --.--%

CRIS --.--%

TMBR --.--%

SLRX --.--%

VCNX --.--%

FRTX --.--%

AKESF --.--%

BPMUF --.--%

Beta

1.4330

Last Div

0.0000

Range

1.15-2.98

Chg

-0.0300

Avg Vol

84777

Mkt Cap

4099179

Exch

NASDAQ

Country

US

Phone

858 925 7049

DCF Diff

-1.1391

DCF

2.4091

Div Yield

0.0000

P/S

0.0000

EV Multiple

-0.3536

P/FV

0.2569

Div Yield %

0.0000

P/E

-0.6148

PEG

-0.0148

Payout

0.0000

Current Ratio

14.5798

Quick Ratio

14.5798

Cash Ratio

2.8654

DSO

0.0000

DIO

0.0000

Op Cycle

0.0000

DPO

0.0000

CCC

0.0000

Gross Margin

0.0000

Op Margin

0.0000

Pretax Margin

0.0000

Net Margin

0.0000

Eff Tax Rate

-0.0066

ROA

-0.3931

ROE

-0.3769

ROCE

-0.4589

NI/EBT

0.9801

EBT/EBIT

0.9291

EBIT/Rev

0.0000

Debt Ratio

0.0021

D/E

0.0022

LT Debt/Cap

0.0000

Total Debt/Cap

0.0022

Int Coverage

53.9516

CF/Debt

-119.0313

Equity Multi

1.0632

Rec Turnover

0.0000

Pay Turnover

0.0000

Inv Turnover

0.0000

FA Turnover

0.0000

Asset Turnover

0.0000

OCF/Share

-1.2916

FCF/Share

-1.2916

Cash/Share

4.3622

OCF/Sales

0.0000

FCF/OCF

1.0000

CF Coverage

-119.0313

ST Coverage

-119.0313

CapEx Coverage

0.0000

Div&CapEx Cov

0.0000

P/BV

0.2569

P/B

0.2569

P/S

0.0000

P/E

-0.6148

P/FCF

-1.0762

P/OCF

-0.9833

P/CF

-0.9833

PEG

-0.0148

P/S

0.0000

EV Multiple

-0.3536

P/FV

0.2569

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jan 23, 08:30 Artelo Biosciences Announces Publication of New Peer-Reviewed Pre-Clinical Research Demonstrating ART26.12’s Effectiveness in Treating and Preventing Oxaliplatin-Induced Peripheral Neuropathy GlobeNewswire Inc. Nov 02, 08:30 Artelo Biosciences to Present Preclinical Data Showcasing Research on ART26.12 and ART12.11 in Anxiety and Depression at Neuroscience 2023

Revenue Product Segmentation